Compound index

Melanocortin Receptor Agonists

Bremelanotide

Also known as PT-141 · Vyleesi

FDA-approved for specific indicationsFDA-approved

Last reviewed: 2026-11-19

History

Developed by Palatin Technologies from melanocortin peptide research; FDA approval followed in 2019.

Key sources

Indication-specific regulatory sources and editorial screen checked November 19, 2026. This is not an exhaustive systematic review; consult current labels.

Related glossary terms